SHANGHAI – June 12, 2026 – Medical diagnostics has taken a major leap forward with the launch of the all-new CK-MB/cTnI/Myo Combo Test Kit, a rapid, point-of-care testing solution designed to dramatically improve the early diagnosis of acute myocardial infarction (AMI). Developed to address the critical “golden hour” of heart attack treatment, this tri-marker kit is poised to become an indispensable tool in emergency rooms, ambulance services, and primary care clinics worldwide.
The test kit simultaneously detects three key cardiac biomarkers: Creatine Kinase-MB (CK-MB), Cardiac Troponin I (cTnI), and Myoglobin (Myo). While Myoglobin appears early to signal possible muscle damage, cTnI offers exceptional specificity for cardiac tissue. CK-MB complements these by helping to confirm infarction and estimate damage size. Alone, each marker has limitations, but combined, they provide a comprehensive, multi-dimensional view of cardiac health.
What sets this Combo Test Kit apart is its speed and simplicity. Utilizing advanced immunochromatography, the kit delivers accurate results from a whole blood, serum, or plasma sample in just 10–15 minutes. The cassette-based design is user-friendly, requiring no specialized equipment or extensive training. A clear, color-coded readout allows medical staff to make swift triage decisions, potentially saving precious minutes when every second counts.
Clinical trials have demonstrated sensitivity and specificity rates exceeding 95% for cTnI detection, matching or surpassing central lab standards. Furthermore, the kit’s ability to analyze three biomarkers from a single sample reduces patient discomfort and lowers overall testing costs.
“We have moved beyond single-marker testing into an era of integrated rapid diagnosis,” said a company spokesperson. “This kit not only speeds up the detection of heart attacks but also helps rule out AMI in patients with chest pain from other causes, reducing unnecessary hospital admissions.”
The CK-MB/cTnI/Myo Combo Test Kit is now available for international distribution, offering a compact, shelf-stable solution that operates at room temperature. For healthcare providers battling the world’s leading cause of death, this innovation represents a new standard of care in cardiac emergency response.
Post time: May-12-2026